Seaport Therapeutics' GlyphAgo Shows Promising Phase 1 Data for Anxiety Treatment — Seaport Therapeutics, Inc.

Event summary

Seaport Therapeutics reported positive multiple-ascending dose (MAD) data from its Phase 1 trial of GlyphAgo™ in healthy volunteers.
GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic profile consistent with previous single-ascending dose (SAD) data.
The trial showed that GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations.
Seaport plans to initiate two parallel Phase 2 trials for GlyphAgo in generalized anxiety disorder (GAD) patients.
Topline data from the Phase 2a proof-of-pharmacology trial is expected in early 2028, and from the Phase 2b trial by the end of 2028.

The big picture

Seaport Therapeutics' positive Phase 1 data for GlyphAgo™ marks a significant step in developing a novel treatment for generalized anxiety disorder. The company's Glyph platform aims to overcome limitations of existing therapies by enhancing lymphatic absorption and reducing liver exposure. This advancement could address a critical unmet need in neuropsychiatric care, potentially offering a new option for patients who have not had a new medicine approved in nearly two decades.

What we're watching

Clinical Development: How the Phase 2 trials will validate GlyphAgo's efficacy and safety in GAD patients.
Regulatory Pathway: Whether the Phase 2b trial will be registration-enabling and accelerate approval timelines.
Market Differentiation: The pace at which GlyphAgo can establish itself as a leading treatment for GAD.